Myelodysplastic Syndromes

Latest News

Patients with LR-MDS, particularly those with the highest rates of infection-related deaths, would benefit from close monitoring for infections. | Image credit: Saiful52 - stock.adobe.com
Infection Linked With Nearly a Quarter of Deaths in Lower-Risk MDS

April 30th 2025

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant monitoring and preventive strategies.

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

April 25th 2025

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

April 11th 2025

ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
ESA Treatment Improves OS in Lower-Risk MDS

March 28th 2025

A newly developed MDS scoring system has similar diagnostic accuracy to a more established, but also more elaborate, system, a new study found. | Image credit: syahrir - stock.adobe.com
ELN Scoring System Shows Similar Accuracy to iFS for MDS Diagnosis

March 26th 2025

More News

MDS wooden blocks | Image Credit: Sviatlana - stock.adobe.com
August 2nd 2024

Report: ESAs Largely Ineffective in Lower-Risk MDS

Jared Kaltwasser
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).
stem cell transplant | Image Credit: Vadim-stock.adobe.com.jpeg
July 28th 2024

HCT Outcomes Show Improvement With Posttransplant Cyclophosphamide

Karen Jacobson-Sive
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.
MDS test | Image Credit: Saiful52-stock.adobe.com
July 22nd 2024

Study Identifies Risk Factors for Progression From Low-Risk MDS

Jared Kaltwasser
The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression.
transfusion setup | Image Credit: Parilov-stock.adobe.com
July 15th 2024

Sponsor Terminates MATTERHORN Trial of Roxadustat for Low-Risk MDS

Jared Kaltwasser
Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.
Telehealth solutions | Image Credit: Dmitry - stock.adobe.com
July 10th 2024

Telehealth Can Drive More Meaningful Serious Illness Conversations in MDS, AML

AJMC Contributor
Researchers collected feedback from 20 clinicians implementing a telehealth serious illness conversation (SIC) with their patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Giving bad news | Image Credit: engagestock-stock.adobe.com
July 3rd 2024

VEXAS Syndrome Often Misdiagnosed as Pyoderma Gangrenosum

AJMC Contributor
In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and with systemic symptoms.
MDS panel | Image Credit: MdBabul-stock.adobe.com
June 27th 2024

Clinicians, Caregivers, Patients: MDS Treatment Preferences Explored

Kimberly Rath, PharmD
Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS).
myelodysplastic disease diagnosis | Image Credit: ibreakstock-stock.adobe.com
June 19th 2024

How Inflammation Factors May Influence Lower-Risk MDS

Gayle Turim Dickstein
Determining the roles that various inflammatory markers and pathways play in lower-risk myelodysplastic syndromes (MDS) could lead to therapies that keep disease progression at bay.
Gut microbiome | Image Credit: © sdecoret - stock.adobe.com
June 13th 2024

Gut Microbiota Found to Influence MDS Risk Through Immune Cells

Kimberly Rath, PharmD
Researchers have identified a causal link between gut microbiota and myelodysplastic syndrome (MDS) risk, mediated by certain key immune cell phenotypes.
Scientific investigation | Image Credit: makibestphoto-stock.adobe.com
June 5th 2024

Consortium: PROs Have Key Role in MDS Trials

Jared Kaltwasser
The coalition said, however, that patient-reported outcomes (PROs) in the myelodysplastic syndrome (MDS) space will be most meaningful if they are collected rigorously and if the data are transparent.
MDS Panel | Image Credit: MdBabul-stock.adobe.com
May 22nd 2024

Key Factors Significantly Associated With ESA Response in Lower-Risk MDS

Luke Halpern
Hemoglobin levels, transfusion independence, and low serum erythropoietin levels were all deemed to have a statistically significant relationship with erythropoiesis-stimulating agent (ESA) response.
MDS blood test | Image Credit: MdBabul-stock.adobe.com
May 16th 2024

Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS

Kimberly Rath, PharmD
Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
MDS graphic | Image Credit: MdBabul-stock.adobe.com
May 8th 2024

Diagnostic Oversights Limit Luspatercept Benefits in MDS

Gayle Turim Dickstein
Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept | Image Credit: © ipopba - stock.adobe.com
April 30th 2024

Machine Learning and Neural Network Can Be Effective Diagnostic Tools in MDS, Study Finds

Jared Kaltwasser
The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.
MDS graphic | Image Credit: Sviatlana - stock.adobe.com
April 15th 2024

Improving Cancer Care: The Role of Oral Hypomethylating Agents and Education

Jared Kaltwasser
Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia.
Myelodysplastic syndrome written on a clipboard | Image Credit: syahrir - stock.adobe.com
April 11th 2024

TP53-Mutated MDS/AML Posttransplant Treatment Gaps

Luke Halpern
The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant vs those who did not.
Laptop with words Myelodysplastic Syndrome | Image Credit:Yurii Kibalnik - stock.adobe.com
April 4th 2024

Heterogeneous Practices Common in Treatment, Monitoring of Patients With Myelodysplastic Syndrome With Del(5q)

Luke Halpern
This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones.
Concept of Meylodysplastic Syndrome | Image Credit: syahrir - stock.adobe.com
March 26th 2024

Venetoclax Resistance in Patients With MDS Explained in New Study

Jared Kaltwasser
The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.
MDS Myelodysplastic syndrome | Image Credit: © Sviatlana - stock.adobe.com.jpeg
March 16th 2024

Luspatercept Benefits Transfusion-Dependent Patients With MDS and Anemia in Real-World Study

Jared Kaltwasser
The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.
Bone marrow from MDS | Image credit: tonaquatic - stock.adobe.com
March 9th 2024

Venetoclax/Azacitidine Shows Promise for Relapse Prevention in High-Risk MDS and AML

Luke Halpern
Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Myelodysplastic disease diagnosis | Image credit: ibreakstock - stock.adobe.com
February 28th 2024

Gene Mutations Linked to Adverse Outcomes in AML/MDS

Gwen Mergian
A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell transplant improved survival in this population.
Blood sample for MDS test | Image Credit: MdBabul - stock.adobe.com
February 22nd 2024

Study Describes Characteristics, Outcomes of Patients With Low-Risk MDS

Jared Kaltwasser
Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).
Letter blocks of MDS | Image credit: Sviatlana-stock.adobe.com
February 22nd 2024

Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML

Laura Joszt, MA
Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Businessman presenting concept about research innovation and experiments | Image credit: NicoElNino - stock.adobe.com
February 6th 2024

Signaling Pathways in MDS a Fruitful Area for Research, Drug Development

Jared Kaltwasser
A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets.
Psychology and mental health, a female patient feeling nervous in a clinic for support | Image credit: KApeopleimages - stock.adobe.com
February 2nd 2024

Uncertainty, Coping Strategies Common Among Patients With AML, High-Risk MDS

Luke Halpern
Patients with comorbid acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) expressed a desire to discuss treatment options and maintain normalcy; they were not willing to have conversations involving their prognosis and future.
Leukemia cells - LASZLO - stock.adobe.com.jpg
January 26th 2024

Oral and IV Decitabine/Cedazuridine Prove Comparable in MDS

Sabrina Serani
The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.
MDS from stone blocks | Image credit: Sviatlana-stock.adobe.com.
January 26th 2024

Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS

AJMC Staff
Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).
Meylodysplastic syndrome | Image Credit: syahrir - stock.adobe.com
January 23rd 2024

Study Highlights Need for Additional Caregiver Support in Higher-Risk MDS

AJMC Staff
The study, which pulled self-reported data from online bulletin boards across the US, Canada, and the United Kingdom in 2020, found that the degree of burden varied based on patient disease stage, among other factors.
Myelodysplastic syndrome | Image Credit: Sviatlana - stock.adobe.com
January 17th 2024

Online Workshop Reveals Patient, Future Research Priorities in MDS

Maggie L. Shaw
Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, quality of life, and communication with the care team.
Top 5 myelodysplastic syndromes articles of 2023
December 22nd 2023

Top 5 Most-Read Myelodysplastic Syndromes Articles of 2023

Mary Caffrey
An August approval of luspatercept, sold as Reblozyl, which promises to alleviate transfusion burdens for patients with lower-risk MDS, was among the news items that drew readers’ attention.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo